本研究的目的是确定早期声门鳞状细胞癌 (EGSCC) 根治性放疗的结果，当预计总治疗时间 (OTT) 延长时，采用增加放疗期间的分次大小的策略。纳入了2008年至2019年间在北海道大学医院接受根治性放射治疗的临床诊断为T1-2N0M0 EGSCC的患者。作为我们的标准治疗方案，患者接受 66 Gy（分 33 次）的 T1 疾病治疗和 70 Gy（分 35 次 T2 疾病）治疗。如果 OTT 预计延长 > 1 周，则剂量分数大小从开始或放疗期间从 2.0 Gy 增加到 2.5 Gy（调整组 [AG]）。这时候我们对UG和AG进行了统计分析。总共确定了116名患者，调整了29名患者的治疗方案。中位随访时间为 60.9 个月。在T1组中，AG中的累积5年局部失败率为12.0％，UG中为15.4％，而在T2组中，AG中的累积局部失败率为40.7％，UG中为25.3％。 AG 和 UG 之间没有显着差异。同样，总生存率和无进展生存率也没有观察到显着差异。我们对 EGSCC 患者的单机构回顾性分析表明，从一开始或在疗程中调整放疗计划以增加分次大小的方法可能会有效维持治疗结果。© 作者 2023。由牛津大学出版社出版代表日本放射线研究会和日本放射线肿瘤学会。

The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.© The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.